Johnson & Johnson accelerates human trial of coronavirus vaccine

Jun 10, 2020 - 02:44 PM
NIH research

Johnson & Johnson today announced it accelerated the initiation of its first human trials of its coronavirus vaccine candidate, with the trial slated to begin in the second half of July.

In J&J’s first human trial, it will combine Phase I, usually a small study to test safety, with a Phase IIA trial to evaluate immune response and effectiveness. Both phases will enroll a total of 1,045 people between 18 and 55 years old and older than 65.

The company in March received $456 million from the Biomedical Advanced Research and Development Authority to develop its vaccine and is one of several being evaluated under Operation Warp Speed, a public-private partnership to facilitate, at an unprecedented pace, the development, manufacturing, and distribution of COVID-19 countermeasures.

Related News Articles

Headline
Recall issued for mislabeled potassium chloride
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
Study finds flu, COVID-19 infection temporarily raises risk of heart attack, stroke 
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
CDC adopts ACIP recommendations for COVID-19, chickenpox vaccines
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
FDA seeks feedback on measuring AI-enabled medical device performance
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
Olympus recalls endoscope needles
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…